5 September 2014Subscribe to our news feed

Effects of testosterone replacement therapy in men with hypogonadism

Effects of testosterone replacement therapy in men with hypogonadism

Alleged concerns regarding risk of cardiovascular disease with testosterone replacement therapy have been promulgated recently. However, a large and growing number of intervention studies show to the contrary that testosterone therapy reduces cardiovascular risk factors and confers multiple beneficial health effects. Thus, fears promoted by some recent flawed studies need to be critically re-evaluated.

This summary gives an overview of a comprehensive review of studies that have investigated health effects and safety of testosterone therapy.1 As outlined here, the position that hypogonadism (also known as testosterone deficiency) should be regarded as a risk factor for cardiovascular disease is supported by a rapidly expanding body of evidence.2-4

KEY POINTS1

  • Testosterone therapy has beneficial effects on body composition:

    • Increased muscle mass
    • Reduced intra-abdominal (visceral) fat mass
    • Reduced total body fat mass
  • Testosterone therapy has beneficial effects on cholesterol and lipid profile:

    • Reduced Total cholesterol (TC)
    • Reduced LDL cholesterol
    • Reduced triglycerides (TGs)
    • Increased HDL levels
  • Testosterone therapy has beneficial effects on cardiovascular function

    • Reduction in indices of atherosclerosis
    • Reduced blood pressure
  • Testosterone therapy has beneficial effects on glucose metabolism, which reduce risk of diabetes:

    • Increased insulin sensitivity
    • Reduced glucose levels
    • Reduced HbA1c levels (a measure of long term glucose control)
  • Testosterone therapy has beneficial effects on inflammatory parameters
  • Testosterone therapy has beneficial effects on longevity:

    • Reduced risk of mortality and improved survival
  • Testosterone therapy has beneficial effects on sexual function:

    • Increased libido, improved erectile function and ejaculatory function
  • Testosterone therapy has beneficial effects on quality of life:

    • Less fatigue and improvement in energy, mood, vitality
  • This review in addition highlights results from multiple long-term registry studies which demonstrate the following key results:5-11

    • Testosterone therapy effectively restores physiological testosterone levels within the first 12 months and these restored testosterone levels are maintained with testosterone therapy throughout the entire study period, which at this point is up to 6 years.
    • Long-term testosterone therapy results in a marked and sustained reduction in body weight and waist circumference (figure 1), BMI, CRP (C-reactive protein; an inflammatory biomarker), HbA1c and improves the lipid profile by reducing total cholesterol, LDL and triglycerides while increasing HDL.
    • It is especially notable that the long-term reductions in body weight, waist circumference and HbA1c keep progressing throughout 5 years, and further improve after each year of testosterone therapy.
  • Safety of testosterone therapy

    • The most common side effects of testosterone therapy are increases in hematocrit and PSA.12, 13 However, these elevations occur within the first 12 months, and thereafter remain stable with continued testosterone therapy for up to 5 years.10 This corroborates findings from a previous 3 year-long study which demonstrated that elevations (within the reference range) of hematocrit and PSA plateau at 12 months and 6 months respectively, after initiation of testosterone therapy.
    • 5 years of testosterone therapy also does not change the International Prostate Symptom Score (IPSS), maximum urinary flow (Qmax) rate, post-void residual (PVR) volume, or prostate size.14 Thus, long-term testosterone therapy does not impact negatively on lower urinary tract symptoms (LUTS) and prostate volume.
Figure 1: Long-term testosterone therapy results in a marked and sustained reduction in body weight and waist circumference
Figure 1:
Effects of long-term testosterone therapy on weight loss (WL) (Panel A), waist circumference (WC) (Panel B). Marked and progressive decrease in weight (WL) (Panel A) and reduction in WC (Pane B) were observed in men with TD who were treated with T for a 5 year period.

From Traish 2014

What is known

Hypogonadism is a common clinical condition. Observational studies report associations of lower testosterone levels with poorer health outcomes in ageing men, including frailty, reduced sexual activity, insulin resistance, cognitive decline, cardiovascular events and mortality.15, 16 Decreased testosterone levels also are associated with increased risks of osteoporosis, metabolic syndrome, type 2 diabetes.17

Men with the metabolic syndrome have lower testosterone levels than age-matched men without the metabolic syndrome18-23, and risk of developing the metabolic syndrome is lower in men with higher testosterone levels.24-28 Similarly, men with type 2 diabetes have lower testosterone levels than men without a history of diabetes29-35, and risk of type 2 diabetes is lower in men with high testosterone levels.36-39 Likewise, men with coronary artery disease have lower testosterone levels than age-matched men without coronary artery disease40, 41, and risk of cardiovascular events42 and cardiovascular death41 is lower in men with high testosterone levels.

What this study adds

A comprehensive review of testosterone therapy interventions confirms that testosterone therapy is safe if treatment and monitoring are appropriately executed. The evidence available to date does not support recently raised concerns about potential detrimental cardiovascular effects of testosterone therapy. Instead, a growing number of interventions studies show that testosterone therapy has multiple beneficial effects;

Thus, there is now ample evidence to argue that testosterone deficiency should be an element in the definition of the metabolic syndrome.43 In the long run, the beneficial effects of testosterone therapy on the metabolic parameters outlined above would protect against development of the main killers; cardiovascular disease and type-2 diabetes. There is a high prevalence of testosterone deficiency in type 2 diabetics,29-35 and because multiple studies demonstrate metabolic benefits of testosterone therapy in type 2 diabetic patients44-49 it has been suggested that testosterone supplementation should be considered when treating type 2 diabetes in hypogonadal men.50 There also are mounting data to support use of testosterone therapy in treatment of obesity.5-11, 51, 52

Low testosterone levels together with standard risk factors can be used to improved health risk prediction, and may represent a valuable biomarker for indication of cardiovascular disease risk.53 Due to the strong associations of low testosterone levels with detrimental health outcomes, it is likely that testosterone deficiency contributes, at least partly, to aging related health deterioration. It has therefore been suggested that testosterone deficiency should be regarded as a risk factor for cardiovascular disease.2-4

References

1. Traish AM. Outcomes of testosterone therapy in men with testosterone deficiency (TD): Part II. Steroids. 2014.
2. Ullah MI, Washington T, Kazi M, et al. Testosterone deficiency as a risk factor for cardiovascular disease. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2011;43(3):153-164.
3. Jones TH. Testosterone deficiency: a risk factor for cardiovascular disease? Trends in endocrinology and metabolism: TEM. 2010;21(8):496-503.
4. Maggio M, Basaria S. Welcoming low testosterone as a cardiovascular risk factor. International journal of impotence research. 2009;21(4):261-264.
5. Saad F, Haider A, Doros G, et al. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity (Silver Spring). 2013;21(10):1975-1981.
6. Haider A, Yassin A, Doros G, et al. Effects of long-term testosterone therapy on patients with "diabesity": results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. International journal of endocrinology. 2014;2014:683515.
7. Yassin A, Doros G. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Clinical obesity. 2013;3(3-4):73-83.
8. Haider A, Saad F, Doros G, et al. Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study. . Obes Res Clin Pract 2013.
9. Traish AM, Haider A, Doros G, et al. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. International journal of clinical practice. 2014;68(3):314-329.
10. Francomano D, Lenzi A, Aversa A. Effects of five-year treatment with testosterone undecanoate on metabolic and hormonal parameters in ageing men with metabolic syndrome. International journal of endocrinology. 2014;2014:527470.
11. Yassin DJ, Doros G, Hammerer PG, et al. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. The journal of sexual medicine. 2014;11(6):1567-1576.
12. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. The Journal of clinical endocrinology and metabolism. 2010;95(6):2536-2559.
13. Zitzmann M, Mattern A, Hanisch J, et al. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. The journal of sexual medicine. 2013;10(2):579-588.
14. Francomano D, Ilacqua A, Bruzziches R, et al. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome. Urology. 2014;83(1):167-173.
15. Yeap BB, Araujo AB, Wittert GA. Do low testosterone levels contribute to ill-health during male ageing? Critical reviews in clinical laboratory sciences. 2012;49(5-6):168-182.
16. Yeap BB. Are declining testosterone levels a major risk factor for ill-health in aging men? International journal of impotence research. 2009;21(1):24-36.
17. Yeap BB. Testosterone and ill-health in aging men. Nature clinical practice Endocrinology & metabolism. 2009;5(2):113-121.
18. Singh SK, Goyal R, Pratyush DD. Is hypoandrogenemia a component of metabolic syndrome in males? Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. 2011;119(1):30-35.
19. Maggio M, Lauretani F, Ceda GP, et al. Association between hormones and metabolic syndrome in older Italian men. Journal of the American Geriatrics Society. 2006;54(12):1832-1838.
20. Garcia-Cruz E, Leibar-Tamayo A, Romero J, et al. Metabolic syndrome in men with low testosterone levels: relationship with cardiovascular risk factors and comorbidities and with erectile dysfunction. The journal of sexual medicine. 2013;10(10):2529-2538.
21. Grosman H, Rosales M, Fabre B, et al. Association between testosterone levels and the metabolic syndrome in adult men. The aging male : the official journal of the International Society for the Study of the Aging Male. 2014:1-5.
22. Bhattacharya RK, Khera M, Blick G, et al. Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS). BMC endocrine disorders. 2011;11:18.
23. Yeap BB, Knuiman MW, Divitini ML, et al. Differential associations of testosterone, dihydrotestosterone and oestradiol with physical, metabolic and health-related factors in community-dwelling men aged 17-97 years from the Busselton Health Survey. Clinical endocrinology. 2014;81(1):100-108.
24. Kupelian V, Page ST, Araujo AB, et al. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. The Journal of clinical endocrinology and metabolism. 2006;91(3):843-850.
25. Rodriguez A, Muller DC, Metter EJ, et al. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. The Journal of clinical endocrinology and metabolism. 2007;92(9):3568-3572.
26. Tsujimura A, Miyagawa Y, Takezawa K, et al. Is low testosterone concentration a risk factor for metabolic syndrome in healthy middle-aged men? Urology. 2013;82(4):814-819.
27. Tong PC, Ho CS, Yeung VT, et al. Association of testosterone, insulin-like growth factor-I, and C-reactive protein with metabolic syndrome in Chinese middle-aged men with a family history of type 2 diabetes. The Journal of clinical endocrinology and metabolism. 2005;90(12):6418-6423.
28. Haring R, Volzke H, Felix SB, et al. Prediction of metabolic syndrome by low serum testosterone levels in men: results from the study of health in Pomerania. Diabetes. 2009;58(9):2027-2031.
29. Grossmann M, Thomas MC, Panagiotopoulos S, et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. The Journal of clinical endocrinology and metabolism. 2008;93(5):1834-1840.
30. Chandel A, Dhindsa S, Topiwala S, et al. Testosterone concentration in young patients with diabetes. Diabetes care. 2008;31(10):2013-2017.
31. Hernandez-Mijares A, Garcia-Malpartida K, Sola-Izquierdo E, et al. Testosterone levels in males with type 2 diabetes and their relationship with cardiovascular risk factors and cardiovascular disease. The journal of sexual medicine. 2010;7(5):1954-1964.
32. Dhindsa S, Miller MG, McWhirter CL, et al. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes care. 2010;33(6):1186-1192.
33. Anderson SG, Heald A, Younger N, et al. Screening for hypogonadism in diabetes 2008/9: results from the Cheshire Primary Care cohort. Primary care diabetes. 2012;6(2):143-148.
34. Ogbera OA, Sonny C, Olufemi F, et al. Hypogonadism and subnormal total testosterone levels in men with type 2 diabetes mellitus. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP. 2011;21(9):517-521.
35. Dhindsa S, Prabhakar S, Sethi M, et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. The Journal of clinical endocrinology and metabolism. 2004;89(11):5462-5468.
36. Ding EL, Song Y, Malik VS, et al. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA : the journal of the American Medical Association. 2006;295(11):1288-1299.
37. Vikan T, Schirmer H, Njolstad I, et al. Low testosterone and sex hormone-binding globulin levels and high estradiol levels are independent predictors of type 2 diabetes in men. European journal of endocrinology / European Federation of Endocrine Societies. 2010;162(4):747-754.
38. Oh JY, Barrett-Connor E, Wedick NM, et al. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes care. 2002;25(1):55-60.
39. Stellato RK, Feldman HA, Hamdy O, et al. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes care. 2000;23(4):490-494.
40. English KM, Mandour O, Steeds RP, et al. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. European heart journal. 2000;21(11):890-894.
41. Malkin CJ, Pugh PJ, Morris PD, et al. Low serum testosterone and increased mortality in men with coronary heart disease. Heart. 2010;96(22):1821-1825.
42. Ohlsson C, Barrett-Connor E, Bhasin S, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. Journal of the American College of Cardiology. 2011;58(16):1674-1681.
43. Saad F, Gooren L. The role of testosterone in the metabolic syndrome: a review. The Journal of steroid biochemistry and molecular biology. 2009;114(1-2):40-43.
44. Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. The aging male : the official journal of the International Society for the Study of the Aging Male. 2003;6(1):1-7.
45. Kapoor D, Goodwin E, Channer KS, et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. European journal of endocrinology / European Federation of Endocrine Societies. 2006;154(6):899-906.
46. Heufelder AE, Saad F, Bunck MC, et al. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. Journal of andrology. 2009;30(6):726-733.
47. Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes care. 2011;34(4):828-837.
48. Mitkov MD, Aleksandrova IY, Orbetzova MM. Effect of transdermal testosterone or alpha-lipoic acid on erectile dysfunction and quality of life in patients with type 2 diabetes mellitus. Folia medica. 2013;55(1):55-63.
49. Cai X, Tian Y, Wu T, et al. Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Asian journal of andrology. 2014;16(1):146-152.
50. Corona G, Mannucci E, Forti G, et al. Following the common association between testosterone deficiency and diabetes mellitus, can testosterone be regarded as a new therapy for diabetes? International journal of andrology. 2009;32(5):431-441.
51. Saad F, Aversa A, Isidori AM, et al. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Current diabetes reviews. 2012;8(2):131-143.
52. Saad F, Gooren LJ. The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2. Journal of obesity. 2011;2011.
53. Vlachopoulos C, Ioakeimidis N, Terentes-Printzios D, et al. Plasma total testosterone and incident cardiovascular events in hypertensive patients. American journal of hypertension. 2013;26(3):373-381.
Last updated: 2017
G.GM.MH.04.2015.0334